PressReleases Investors Home Press Releases Events & Presentations Financials & Filings Stock Information Governance Year All2024202320222021202020192018 Dec 03, 2024 Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 20, 2024 Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer Nov 13, 2024 Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress Nov 11, 2024 Mural Oncology to Participate in Two Upcoming Investor Conferences Nov 07, 2024 Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Nov 04, 2024 Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 07, 2024 Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Oct 02, 2024 Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 26, 2024 Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress Sep 23, 2024 Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi Print page >> Contact us >> RSS >> Email alerts >>
Year All2024202320222021202020192018 Dec 03, 2024 Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 20, 2024 Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer Nov 13, 2024 Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress Nov 11, 2024 Mural Oncology to Participate in Two Upcoming Investor Conferences Nov 07, 2024 Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Nov 04, 2024 Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 07, 2024 Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Oct 02, 2024 Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 26, 2024 Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress Sep 23, 2024 Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
Nov 20, 2024 Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Nov 13, 2024 Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
Nov 07, 2024 Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Oct 07, 2024 Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
